David P Nichols

17PUBLICATIONS
28CO-AUTHORS
Fluid-structure interaction and aeroacousticsFlight dynamicsRespiratory diseasesMicrofluidics and nanofluidicsTe mātauranga Māori i roto i te mātauranga (Mātauranga Māori in education)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 17, 2025
Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.

Scott D Sagel, T Spencer Poore, Brandie D Wagner

|Aug 27, 2024
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces Aspergillus fumigatus in Cystic Fibrosis.

Sarah J Morgan, David P Nichols, Windy Ni

|Jul 23, 2024
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.

Nicole Mayer-Hamblett, Alex H Gifford, Margaret Kloster

|Nov 29, 2023
Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.

David Nichols, Alex Gifford, Renee Russell

|Mar 31, 2022
Reply to Martin et al.: Change in Lung Function after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Do Not Forget Anatomy!

David P Nichols, Steven M Rowe

|Mar 15, 2022
Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Pseudomonas aeruginosa.

Jonathan D Cogen, Anna V Faino, Frankline Onchiri

Pageof 3

Frequent Collaborators

3 joint publications

Steven M Rowe

2 joint publications

Scott D Sagel

1 joint publications

Scott B Drutman

1 joint publications

Jordan K Abbott